Vaccines

Trinity Health Announces COVID-19 Vaccine Requirement for All Colleagues

Retrieved on: 
Thursday, July 8, 2021
Medical specialties, Medicine, Trinity Health, Vaccine, Health sciences, Vaccines, COVID-19 vaccines, Clinical trials

LIVONIA, Mich., July 8, 2021 /PRNewswire/ --Trinity Health today announced, effective immediately, the national health system will require all colleagues, clinical staff, contractors, and those conducting business in its health care facilities to be vaccinated against COVID-19.

Key Points: 
  • LIVONIA, Mich., July 8, 2021 /PRNewswire/ --Trinity Health today announced, effective immediately, the national health system will require all colleagues, clinical staff, contractors, and those conducting business in its health care facilities to be vaccinated against COVID-19.
  • Since December 2020,when the U.S. Food and Drug Administration approved the first vaccine for Emergency Use Authorization, Trinity Health has strongly encouraged vaccination for all colleagues and within the communities its various Health Ministries serve.
  • To date, the health system estimates nearly 75% of Trinity Health employees have already received at least one dose of the vaccineand it now looks to close the gap with this new requirement.
  • "Over the last year, Trinity Health has counted our own colleagues and patients in the too-high coronavirus death toll.

Vaccitech to Present at the William Blair Biotech Focus Conference 2021

Retrieved on: 
Thursday, July 8, 2021
Health sciences, Medicine, Health care, Medical research, Vaccines, Vaccitech, Oxford–AstraZeneca COVID-19 vaccine, AstraZeneca, Vaccine

A live webcast of the presentation can be accessed through the Events section of the Vaccitech website.

Key Points: 
  • A live webcast of the presentation can be accessed through the Events section of the Vaccitech website.
  • Following the live webcast, a replay will be available at the same location.
  • Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer.
  • Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

Human Papillomavirus (HPV) Vaccines Disease Analysis Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Infectious diseases, Pharmaceutical, Health, Medical devices, Cancer, Clinical medicine, Medicine, Papillomavirus, Infectious causes of cancer, Vaccines, Cancer vaccines, Gynaecological cancer, Human papillomavirus infection, Papillomaviridae, Cervical cancer, Papilloma

The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • Worldwide vaccination programs for human papillomavirus (HPV) have evolved substantially over the last decade.
  • HPV infection is the major cause of cervical cancers, with almost all cases (99%) being caused by HPV infection.
  • Both vaccines are based on the recombinant expression of major capsid antigen L1 from different HPV serotypes, which self-assemble into virus-like particles (VLPs).

2021 Report on Seasonal Influenza Vaccines - Market is Expected to Expand Over Next 10 Years - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Infectious diseases, Pharmaceutical, Health, Medical specialties, Vaccination, Health care, Vaccines, Influenza vaccines, Animal virology, Influenza, Influenza vaccine, Live attenuated influenza vaccine, Flu season, Vaccine, Sanofi

The "Disease Analysis: Seasonal Influenza Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Seasonal Influenza Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • Two types of influenza virus are predominant in humans, types A and B, which circulate annually between late fall and early spring, causing seasonal epidemics.
  • Three major manufacturers dominate the seasonal influenza vaccines market, namely GlaxoSmithKline, Seqirus, and Sanofi, with 2020 vaccines sales of $1,023m, $952m (June 2019 to June 2020), and $2,953m, respectively.
  • Additionally, AstraZeneca's FluMist QIV has recovered its footing in the influenza market, matching its previous peak sales of $295m.

Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine

Retrieved on: 
Wednesday, July 7, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Vaccines, Vaccination, Drugs, Clinical trials, COVID-19 vaccines, RNA vaccines, Medical research, Moderna, RNA vaccine, Influenza vaccine, Vaccine, Live attenuated influenza vaccine

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participants have been dosed in the Phase 1/2 study of mRNA-1010, the Companys quadrivalent seasonal influenza mRNA vaccine candidate.

Key Points: 
  • Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participants have been dosed in the Phase 1/2 study of mRNA-1010, the Companys quadrivalent seasonal influenza mRNA vaccine candidate.
  • This Phase 1/2 randomized, stratified, observer-blind, dose-ranging study will evaluate the safety, reactogenicity and immunogenicity of mRNA-1010, Modernas seasonal influenza vaccine candidate in healthy adults 18 years and older in the U.S.
  • We are pleased to have begun this Phase 1/2 study of mRNA-1010, our first mRNA seasonal flu vaccine candidate to enter the clinic.
  • We expect that our seasonal influenza vaccine candidates will be an important component of our future combination respiratory vaccines, said Stphane Bancel, Chief Executive Officer of Moderna.

Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset

Retrieved on: 
Wednesday, July 7, 2021
Life sciences, Biotechnology, Vaccines, Medical research, Vaxart, Health sciences

"This agreement represents another potential value creation lever for Vaxart, even as Vaxart puts its primary emphasis on the development of oral vaccines.

Key Points: 
  • "This agreement represents another potential value creation lever for Vaxart, even as Vaxart puts its primary emphasis on the development of oral vaccines.
  • Having a partner such as Altesa, led by a scientist and entrepreneur of George Painters stature, will accelerate Vapendavir's development."
  • Under the terms of the agreement, Altesa is granted the worldwide, exclusive right to develop, manufacture, and commercialize Vaxarts proprietary formulation of Vapendavir.
  • Dr George Painter said, We are excited to expand the pipeline of novel antivirals through this licensing agreement with Vaxart.

Worldwide Vaccine Delivery Devices Industry to 2026 - Featuring BD, Corium and Smiths Medical Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Health, General Health, Medical specialties, Medicine, Vaccination, Vaccine, Virology, Health sciences, Vaccines, Medical research, Influenza vaccine, Deployment of COVID-19 vaccines

This report provides a detailed description of vaccine delivery devices and the latest technologies in the market.

Key Points: 
  • This report provides a detailed description of vaccine delivery devices and the latest technologies in the market.
  • The report includes market estimates for different types of vaccine delivery devices.
  • Based on end-users, the vaccine delivery device market is segmented into hospitals, clinics and other end-users (vaccination centers, tertiary care centers, etc.).
  • This report also discusses competition in the global vaccine delivery device market and the key players' strategies and performances.

Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax

Retrieved on: 
Tuesday, July 6, 2021
Medical specialties, Life sciences, Health, Immunology, Biotechnology, Immunogenicity, Vaccines, Biopharmaceutical, ImmunoGen, Glycogen storage disease type II

At the FDA, she oversaw the regulation and approval of numerous protein therapeutics and served as expert consultant to the National Institute of Health's Immune Tolerance Network.

Key Points: 
  • At the FDA, she oversaw the regulation and approval of numerous protein therapeutics and served as expert consultant to the National Institute of Health's Immune Tolerance Network.
  • Amy and I look forward to sharing her vast experience with EpiVax aficionados during our ' Fearless Science World tour ' this fall and winter."
  • Dr. Rosenberg will also work with EpiVax scientists on a range of internal research programs, listed below:
    Personalized Immunogenicity Assessment for Biologics (PIMA): Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease .
  • EpiVax's immunogenicity screening toolkits for therapeutics (ISPRI) and vaccines (iVAX) , are employed in advancing the research of a global roster of companies.

Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate

Retrieved on: 
Tuesday, July 6, 2021
Vaccines, Medical specialties, Medicine, COVID-19 vaccines, Clinical trials, COVID-19 vaccine, Vaccine, Immunologic adjuvant, Hepatitis B vaccine, VLA2001

"We are pleased to collaborate with Dynavax, and our collaboration will produce yet another vital vaccine against the spread of COVID-19.

Key Points: 
  • "We are pleased to collaborate with Dynavax, and our collaboration will produce yet another vital vaccine against the spread of COVID-19.
  • Dynavax developed CpG 1018 adjuvant to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.
  • CpG 1018 adjuvant provides a well-developed technology and a significant safety database, potentially accelerating the development and large-scale manufacturing of a COVID-19 vaccine.
  • Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships.

Travel Advisory - REMINDER - On July 5th, fully vaccinated travellers eligible to enter Canada can benefit from reduced public health measures

Retrieved on: 
Friday, July 2, 2021
Medical specialties, Health, Medicine, Vaccines, Passports, Prevention, Quarantine, Tropical diseases, International Certificate of Vaccination or Prophylaxis, Meningococcal vaccine

It is important to note that travellers arriving before 12:01 a.m. EDT on July 5th will not be eligible for the reduced public health measures.

Key Points: 
  • It is important to note that travellers arriving before 12:01 a.m. EDT on July 5th will not be eligible for the reduced public health measures.
  • This means that travellers who have recently returned to Canada must continue and complete their 14-day quarantine and day 8 test.
  • These changes are only applicable to fully vaccinated travellers who are currently eligible to enter Canada.
  • To benefit from the reduced public health measures, travellers must:
    Be fully vaccinated : To be considered fully vaccinated, a traveller must have received the full series of a vaccine or combination of vaccines accepted by the Government of Canada at least 14 days prior to entering Canada.